Milestone Pharmaceuticals (MIST)
(Delayed Data from NSDQ)
$1.49 USD
+0.06 (4.20%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $1.48 -0.01 (-0.67%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Milestone Pharmaceuticals Inc.'s return on equity, or ROE, is -329.85% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.55%. While this shows that MIST has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
MIST 1.49 +0.06(4.20%)
Will MIST be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MIST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MIST
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
MIST Stock Falls 66% Following Complete Response Letter for Cardamyst
MIST: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright
Other News for MIST
Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution
12 Health Care Stocks Moving In Friday's Intraday Session
Milestone Pharmaceuticals (MIST) Shares Plummet After $52.5 Million Offering Announcement
Milestone Pharmaceuticals plunges after pricing $52.5M offering
Dow Dips Over 200 Points; Levi Strauss Posts Upbeat Earnings